US FDA Guidances Tread Lightly On Trial Population Language

 
• By Michael McCaughan
  
The FDA continues to recommend clinical trials for drug development include representative populations, despite the Trump Administration's anti-DEI push. (Shutterstock)

More from Diversity & Inclusion

More from United States